Publications by authors named "Deepa Lalla"

Claim this Profile
R
Risk of Subsequent Breast Cancer in Women with Early Stage HER2-Positive Breast Cancer in a Large Community Health Plan.
Reina Haque, Lie Hong Chen, Nina Oestreicher, Deepa Lalla, Rowan T Chlebowski

Breast Cancer (Dove Med Press)· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Residual Disease Burden After Neoadjuvant Therapy Among US Patients With High-Risk HER2-positive Early-Stage Breast Cancer: A Population Effectiveness Model.
Nathaniel Hendrix, Nina Oestreicher, Deepa Lalla, Chantal M Dolan, Kathryn A Fisher

Clin Breast Cancer· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health Care Resource Utilization and Costs for Metastatic Breast Cancer Patients Newly Treated with Human Epidermal Growth Factor Receptor 2 (HER2)-Targeted Agents.
Reshma Mahtani, Nina Oestreicher, Deepa Lalla, Augustina Ogbonnaya, Vishal Saundankar

Clin Breast Cancer· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential Delays in Diagnosis of Idiopathic Pulmonary Fibrosis in Medicare Beneficiaries.
Joshua Mooney, Eunice Chang, Deepa Lalla, Elya Papoyan, Karina Raimundo

Ann Am Thorac Soc· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
What is the value of conducting a trial of r-tPA for the treatment of mild stroke patients?
Gregory F Guzauskas, Er Chen, Deepa Lalla, Elaine Yu, Darren Tayama

Int J Stroke· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality adjusted life year gains associated with administration of recombinant tissue-type plasminogen activator for treatment of acute ischemic stroke: 1998-2011.
Deborah P Lubeck, Mark D Danese, Jennifer Duryea, Marc Halperin, Darren Tayama, Deepa Lalla

Int J Stroke· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Symptom burden and quality of life among women with HER2(+) metastatic breast cancer.
Musa Mayer, Kathleen Lang, Sara Hurvitz, Deepa Lalla, Victoria Federico

Breast J· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimated Life-Years Saved in Women with HER2-Positive Metastatic Breast Cancer Receiving First-Line Trastuzumab and Pertuzumab in the United States.
Mark D Danese, Anthony Masaquel, Eduardo Santos, Melissa Brammer, Abraham Lee, Deepa Lalla

Value Health· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Willingness to pay to avoid metastatic breast cancer treatment side effects: results from a conjoint analysis.
Deepa Lalla, Rashad Carlton, Eduardo Santos, Thomas Bramley, Anna D'Souza

Springerplus· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Lifetime Economic Burden of Inaccurate HER2 Testing: Estimating the Costs of False-Positive and False-Negative HER2 Test Results in US Patients with Early-Stage Breast Cancer.
Louis P Garrison, Joseph B Babigumira, Anthony Masaquel, Bruce C M Wang, Deepa Lalla

Value Health· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of recombinant tissue-type plasminogen activator within 3 hours of acute ischemic stroke: current evidence.
Denise M Boudreau, Gregory F Guzauskas, Er Chen, Deepa Lalla, Darren Tayama

Stroke· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer.
Peter A Kaufman, Kenneth J Bloom, Howard Burris, Julie R Gralow, Musa Mayer, Deepa Lalla

Cancer· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world setting.
Sara Hurvitz, Annie Guerin, Melissa Brammer, Ellie Guardino, Zheng-Yi Zhou, Deepa Lalla

Oncologist· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimens.
Ryan N Hansen, Scott D Ramsey, Deepa Lalla, Anthony Masaquel, Tripthi Kamath

Springerplus· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of treatment patterns and economic outcomes in metastatic breast cancer patients initiated on trastuzumab versus lapatinib: a retrospective analysis.
Annie Guérin, Deepa Lalla, Geneviève Gauthier, Amy Styles, Eric Q Wu

Springerplus· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health care utilization and costs by site of service for nonmetastatic breast cancer patients treated with trastuzumab.
Anju Parthan, Eduardo Santos, Laura Becker, Arthur Small, Deepa Lalla

J Manag Care Spec Pharm· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early treatment discontinuation and switching in first-line metastatic breast cancer: the role of patient-reported symptom burden.
Mark S Walker, Anthony S Masaquel, Jiandong Kerr, Deepa Lalla, Oyewale Abidoye

Breast Cancer Res Treat· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 Study.
Heather-Jane Au, Wolfgang Eiermann, Nicholas J Robert, Tadeusz Pienkowski, John Crown, Deepa Lalla

Oncologist· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer.
Manfred Welslau, Veronique Diéras, Joo-Hyuk Sohn, Sara A Hurvitz, Deepa Lalla

Cancer· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of the metastatic breast cancer progression (MBC-P) questionnaire to assess the value of progression-free survival for women with metastatic breast cancer.
Sara A Hurvitz, Deepa Lalla, Ross D Crosby, Susan D Mathias

Breast Cancer Res Treat· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status.
Louis P Garrison, Deepa Lalla, Melissa Brammer, Joseph B Babigumira, Bruce Wang

Cancer· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of central nervous system metastases on treatment discontinuation and survival in older women receiving trastuzumab for metastatic breast cancer.
Mark D Danese, Karla Lindquist, Justin Doan, Deepa Lalla, Melissa Brammer

J Cancer Epidemiol· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Infused therapy and survival in older patients diagnosed with metastatic breast cancer who received trastuzumab.
Robert I Griffiths, Deepa Lalla, Robert J Herbert, Justin F Doan, Melissa G Brammer

Cancer Invest· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimating recurrences prevented from using trastuzumab in HER-2/neu-positive adjuvant breast cancer in the United States.
Mark D Danese, Deepa Lalla, Melissa Brammer, Quan Doan, Kevin Knopf

Cancer· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of trastuzumab on health-related quality of life in patients with HER2-positive metastatic breast cancer: data from three clinical trials.
Hope Rugo, Melissa Brammer, Fan Zhang, Deepa Lalla

Clin Breast Cancer· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis